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We measured antiphospholipid antibodies in sera from 94 
patients with myasthenia gravis (MG). We found lgG aCL in 
14/94 (14.9 % ), lgM aCL in 6/94 (6.4 %) and LA in 4/56 
(7.1 %) patients with MG. As a whole 21 of 94 (22.3 % ) 
patients with MG had some aPL. There was no correlation 
between the presence of aPL and the severity of MG, the 
presence of hyperplasia of thymus, titer of the anti-
acetylcholine receptor antibodies or anti-single stranded 
DNA antibodies. Though the percentage of malignant 
thymoma with aPL were higher than that of malignant 
thymoma without aPL, we thought that aPL were not the 
specific antibody in malignant thymoma. In MG, aPL did 
not play as the aCL syndrome and seemed to be non-specific 
antibodies.
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Introduction 
Anticardiolipin antibodies (aCA) belong to antibodies 
directed against anionic phospholipids 1), and have been 
reported in many clinical systemic syndromes. Most of 
these syndromes are related to lupus erythematosus')2), but 
are not specific for this disease'). They include neurologic 
diseases which appear as ischemic thrombotic episodes 
affecting the arterial or venous system's 5) . Other non-
stroke syndromes such as myelopathy 6) , Guillain-Barre 
syndrome') , migraine') , chorea') , seizures 10) and 
autoimmune neurological diseases'", have been also de-
scribed in association with raised aCL levels. 
 In myasthenia gravis (MG), an autoimmune response to 
the acetylcholine receptor (AChR) in postsynaptic mem-
brane, neuromuscular transmission is impaired 12)'3) Colaco 
et al. described that aCA were detected in sera of patients 
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with multiple sclerosis, MG and Lambert-Eaton 
myasthenic syndrome"). But Rombos et al") reported that 
there was no significant difference of serum aCA level 
between MG and the controls. Therefore, relationship 
between aCA and MG is still not well defined. 
 In this report, measured antiphospholipid antibodies 
(aPL), aCA and lupus anticoagulant (LA) in sera of 
patients with MG and investigated the significance of 
these antibodies in MG. 
Materials and methods 
Ninety-four MG patients (31 men and 63 women) were 
studied. They were diagnosed according to the clinical 
findings, the electromyography (Harvay-Musland test), 
Tensilon test, the titer of anti-AChR antibodies" and 
deposition of immune complexes at the motor end-
plates 16) All blood samples were kept at -70°C until exami-
nation. Control sera from 140 healthy subjects were 
available. 
Anticaradiolipin antibody assay 
The levels of 1gG and 1gM to aCL were determined by the 
solid phase enzyme-linked immunosorbent assay with some 
modifications. In brief, cardiolipin (Sigma, USA) was 
diluted in ethanol and used to coat microtiter plates with 
100 # 1 (5 g g/ml). The plates were dried and washed three 
times with PBST (0.01MPBS, 0.05 % Tween) buffer. The 
antigen-coated plates were blocked with normal rabbit 
serum in PBS. The plates were incubated with test sera 
diluted to 1:50 in the same buffer for 90 minutes (100 m ,u 1 
/well), and washed in PBST followed by a 90 minutes 
incubation with 100 ,a 1 of peroxidase conjugated goat 
anti-human lgG or 1gM (DAKO, Japan). After 3 times of 
washing, color was developed using o-phenylenediamine 
(WAKO Pure Chem Indust, Japan) and the reaction was 
stopped by the addition of 2.5 M H2SO9. The optical density 
(0. D) was measured at 490 nm using an ELISA microtiter 
reader. The O.D values and positive values of lgG and 1gM
in healthy individuals were 0.105, 0.173 and 4.1 %, 2.7 % 
respectively. The ratio of the O.D of patients to the 
control was cut off index and the positive was defined as 
greater than 1.0. Comparisons were made with x2 analysis. 
Lupus anticoagulant activity 
The tissue thromboplastin inhibition was performed 17). The 
ratio of clotting times at 1:100 and 1:1000 dilutions of 
thromboplastin were determined. A ratio of 1.3 or greater 
was defined positive. 
Autoantibody testing 
Anti-AChR antibodies were assayed by an 
immunoprecipitation method using human junctional 
AChR as the antigen"'. Antinuclear antibodies were 
detected by indirect immunof luorescence method. lgG-
class antibodies to single-stranded (ss) and double-
stranded (ds) DNA were detected by ELISA kit (MBL, 
Japan). 2 U/ml or greater was defined positive. 
Results 
Antiphospholipid antibodies in MG 
Raised aCL activity was detected in 19/94 (20.2 %) 
patients with MG (Fig. 1). Positive of only 1gG aCL was 
12, only 1gM was 4 and both of them was 2. LA was
examined in 56 patients with MG. LA was detected in 4/56 
(7.1 %). Two cases had aCL too. In this data, aPL was 
detected in 21/94 (22.3 %). 
Features of 21 MG patients with antiphospholipid anti-
bodies 
In 21 MG patients with aPL, the clinical features and 
laboratory data were shown (Table 1, 2, 3). Three patients 
were ocular type and the others were generalized type. In 
their complications, rheumatoid arthritis, schizophrenia, 
nephrosis and malignant alopecia were observed. In the 
histology of the thymus, 5 patients had hyperplasia and 6 
had thymoma (5 were malignent). The number of hyper-
plasia of thymus and thymoma were not significantly 
different in the two groups. But the number of malignant 
thymoma were higher in this group (5/21, 23.8 %) than in 
the patients without aPL (3/73, 4.1 %) (P<0.005). There 
were no patients who had the history of coagulopathy, 
thrombocytopenia and spontaneous abortion. 
Titer of the anti-AChR antibodies were 13.8 ±28.7nM, and 
there were no significant differentce in comparison to 
another 73 MG patients. Two patients with LA had the 
prolongation of active partial thromboplastin time. Only 
one patient had a false-positive VDRL. Antinuclear 
antibodies were positive in 5/21 (23.8 %). Though anti-
ssDNA antibodies were positive in 12/21 (57.1 %), there 
was no significant difference in two groups. Anti-ds DNA 
antibodies in all patients were negative.
Table 1. Clinical data for MG patients with aPL 
                        severity thymectomy anti- steroid 
  case age/sex AChR Ab complication                    (P
atters) (histology) (nM) therapy 
   1 37/M I - 0.8 - -
   2 30/F I - 0.5 - -
   3 31/M I +(thymic tissue) * 2.2 - -
   4 26/F II a +(thymic tissue) 43.0 - +
   5 44/F II a +(hyperplasia) 35.6 - -
   6 47/F II a +(thymic tissue) 0.8 - +
   7 57/F It a - 20.0 - -
   8 40/M II a +(hyperplasia) 2.4 - -
   9 60/F II a +(thymoma) 11.2 schizophrenia +
   10 42/F 11 a - 26.0 - -
  11 55/F II a +(thymic tissue) 21.2 - + 
  12 54/M II a - 12.7 rheumatoid arthritis -
  13 52/M II a +(malignant thymoma) 0.6 - +
  14 30/F II a +(hyperplasia) 89.2 nephrosis + 
  15 46/F II a +(thymic tissue) 69.2 - -
   16 53/F II a - 68.0 - +
  17 46/F II a +(hyperplasia) 64.6 - -
  18 70/F II b +(malignant thymoma) 2.1 - +
   19 59/F II c -(malignant thymoma) * * 11.7 - +
  20 67/M II c +(malignant thymoma) 31.3 - + 
  21 45/M II c +(mali nant th moma) 72.4 malignant alo ecia + 
* residual thymic tissue 
* * autopsy case
Table 2. Laboratory data for MG patients with aPL 
                                                    anti-DNA Ab(U/ml) 
    case BFP ANA LA PT(%) APTT(sec', 
                                                           ss ds 
          1 - - - 0.9 0.4 
       2 - - + 0.6 0.3 103 36.7 
         3 - - 0.7 0.3 
       4 - - + 1.8 0.7 103 36.6 
         5 - - - 10.6 0.9 
       6 - - - 0.5 0.3 106 25.0 
        7 - - - 25.3 1.8 81 34.4
       8 - 40 X + 3.2 0.8 
       9 - - - 0.7 0.6 119 29.6 
       10 - - - 3.0 0.7 115 30.3 
       11 - - 1.8 1.0 79 33.8 
        12 - - 4.3 0.6 
        13 - - 0.9 0.2
      14 - 160 X 10.2 0.2
        15 - - 0.7 0.4
        16 - - 5.1 1.3
       17 - - 70.1 1.5
      18 - 40X 14.0 1.7
       19 - - 49.6 0.9
        20 - - 2.2 0.9
      21 - 80X 15.9 0.8
BFP: biological false positive for serological tests for syphilis 
ANA: anti-nuclear antibody 
LA: lupus anticoagulant 
ssDNA: single-stranded DNA 
dsDNA: double-stranded DNA 
PT: prothrombin time 
APTT: active partial thromboplastin time
Table 3. Correlation of clinical features and aPL in MG 
patients 
                           aPL(+) aPL(-) 
                            (n = 21) (n = 73)
Type 
    ocular 3 18 
    generalized 18 55 
Thymus 
    hyperplasia 5 10 
    thymoma 6 16 
   (malignant th moma) * (5) (3) 
 Anti-AChR Ab(nM) [mean-!-SD] 27.9±28.7 25.2±91.4 
* significantly different (p<0.005)
Discussion 
ACL are found in various clinical conditions including 
infections and connective tissue disease') 13> APL are 
associated with clinical complications such as 
thrombocytopenia, deep-vein thrombosis and spontaneous 
abortion in autoimmune disorders 19). These antibodies have 
been found in the patients with some neurological diseases, 
because they cross-react with the brain phospholipids 
cephalin and sphingomyelin 21) 21>. 
 In the present study, we detected aPL in sera of MG 
patients; lgG aCL in 14/94 (14.9 %), 1gM aCL in 6/94 (6.4 
%) and LA in 4/56 (7.1 %). Therefore, 21 MG patients 
(22.3 %) had some aPL, and our data are not in agreement
with those of Colaco et al. according to which, 1gM aCL 
were more specific in MG than lgG aCL 11). There is rela-
tively little cross-reactivity of the aCL with anti-DNA 
antibodies 22). This may be because the glyceride portion of 
the phospholipid is essential for antibody binding 23) l) . 
These findings raise the possibility that membrane bound 
phospholipids in association with autologous or exogenous 
membrane antigens might play a role for the development 
of autoimmunity ". But in our study, anti-ssDNA antibod-
ies were positive in 12/21 (57.1 %) MG patients with aCL 
and in 26/73 (35.6 %) MG patients without aCL, and no 
significant difference in anti-ssDNA antibodies between 
these two groups. Though in the complication of thymoma 
these two groups had no significant difference, the percen-
tage of the malignant thymoma was higher in aCL posi-
tive group than in negative group. Thymic hyperplasia and 
thymoma are thought to play a crucial role in the 
pathogenesis of MG and the antiskeletal muscle antibodies 
is reported to be specific or closely associated with 
thymoma 25). In the malignant thymoma with aPL, the 
patients were small number and 4 of them had anti-ssDNA 
antibodies. Though aPL were secondly detected by the 
tissue damage, we thought that aPL were not specific 
antibodies in the malignant thymoma. In MG, aPL were 
thought not to play as the aPL syndrome and had no 
correlation with severity of the MG and anti-AChR 
antibodies. In conclusion, aPL were detected in about 20 %
of MG patients but we could not observe the relation 
between these antibodies and MG. These data suggest that 
these antibodies had no activity of the aPL syndrome and 
were non-functional as polyclonal antibodies in MG. 
 Further studies are needed to confirm the relationship of 
these antibodies and pathogenesis of MG.
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